The volume of information about the treatment and prevention of COVID-19 over the past year has been dizzying. This situation is a powerful reminder of the value of the scientific process, peer review of literature and thoughtful production of treatment guidelines we follow as doctors every day in practice. Fortunately, as we are now almost two years into the pandemic, we have strong, evidence based guidelines from the CDC, NIH and ISDA guiding us as clinicians. Our practice and all of our providers are committed to following these recommedations. If you have questions about other potential approaches to treatment or prevention of COVID-19, please feel free to discuss these with your provider and know that our clinical care will be based on information from trusted infectious disease professional.
Monoclonal antibodies are an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized patients ages 12 and up who are at least 88 pounds and are at high risk for developing severe COVID-19 disease. The treatment can also be given to those at high risk of severe COVID-19 disease following an exposure to COVID and before they develop symptoms or have a positive test.
Here is a link to the Department of Health and Human Services information on monoclonal antibodies.
The treatment can be given through an IV or with subcutaneous injections.
Due to staffing shortages we are not currently offering monoclonal antibody therapy at MPFC. Information on monoclonal antibody therapy in Anchorage can be found by calling the Covid helpline at 907-646-3322 or calling the Fairweather infusion site at Takahtnu Commons at 907-764-3142.